Glen Apseloff
Columbus, OHNPI 1578581336
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,938 of the $70,074 with a category attached, or 65.6%. Purdue Pharma L.p. accounts for 86.1% of it on its own, with 1 other manufacturer making up the rest.
Across 8 payments — averaging $8759.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Purdue Pharma L.p.$60K
- Imbrium Therapeutics L.p.$10K
Across 60 payments — averaging $191,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Purdue Pharma L.p.$11.5M
What the payments were for
- Consulting fees$45,93866%
- Education$24,13634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Purdue Pharma L.p. | 5 | $60,359 |
| Imbrium Therapeutics L.p. | 3 | $9,715 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NALMEFENE HYDROCHLORIDE$15,955
- Zurnai$4,086
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.